Pharma major Lupin Ltd., said its subsidiary Lupin Pharmaceuticals Inc. had launched its Fenofibrate tablets in 48 mg and 145 mg strengths in the US, for which it had received final approval from the US FDA.
Lupin's Fenofibrate tablets are the AB rated generic equivalent of Abbott's Tricor tablets and are indicated for primary hypercholesterolemia or mixed dyslipidemia and severe hypertriglyceridemia.
Abbott's Tricor tables, 48 mg and 145 mg, had sales of $1.26 billion as per IMS Health, June 2012.
Commenting on the approval, Lupin Pharmaceuticals CEO and Group President Vinita Gupta said, "We are very happy to bring this product to market in the US. Patients can be assured that they are receiving the same high quality product they have been accustomed to a a more affordable price."
At the BSE, Lupin shares are currently trading at Rs.565.50, up 0.60 percent from the previous close.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org